Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

Alzheimer’s disease (AD) is the most common form of neurodegeneration and dementia. The endocannabinoid (ECB) system has been proposed as a novel therapeutic target to treat AD. The present study explores the expression of the ECB system, the ECB-related receptor GPR55, and cognitive functions (nove...

Full description

Bibliographic Details
Main Authors: Dina Medina-Vera, Cristina Rosell-Valle, Antonio J. López-Gambero, Juan A. Navarro, Emma N. Zambrana-Infantes, Patricia Rivera, Luis J. Santín, Juan Suarez, Fernando Rodríguez de Fonseca
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Biology
Subjects:
Alzheimer’s disease
5xFAD
endocannabinoid system
amyloid-β
neuroinflammation
GPR55
Online Access:https://www.mdpi.com/2079-7737/9/11/377

Internet

https://www.mdpi.com/2079-7737/9/11/377

Similar Items